Investment Thesis
Vaxcyte is a pre-revenue biotech company incurring massive operating losses (-$345.9M) and burning cash at an unsustainable rate (-$280.6M annually). While the balance sheet is fortress-like with $3.0B equity and no debt, current fundamentals show zero revenue generation and depleting cash resources relative to burn rate, making near-term survival dependent on successful drug commercialization or dilutive financing.
Strengths
- Fortress balance sheet with $3.0B stockholders equity and minimal debt (0.00x D/E)
- Exceptional liquidity position with 7.49x current ratio and $260.8M cash reserves
- Low capital intensity ($2.1M capex) suggests lean operational structure for R&D stage
- Large asset base ($3.3B) provides some downside protection
Risks
- Pre-revenue/zero commercial traction with no path to profitability visible
- Annual cash burn of $280.6M against $260.8M cash position is unsustainable without additional funding
- Massive operating losses (-$345.9M) and negative margins indicate capital-intensive drug development phase
- Dilution risk high from inevitable future equity raises to fund continued operations
- Biotech execution risk: success entirely dependent on drug development, clinical trials, and FDA approval
- Negative ROE (-10.7%) and ROA (-9.6%) reflect shareholder value destruction
Key Metrics to Watch
- Cash runway and burn rate trend relative to clinical trial progress milestones
- Revenue generation from any approved or commercialized products
- Operating expense reduction efficiency and R&D productivity metrics
- Equity dilution from future capital raises and implied cost per share
- Phase progression of pipeline candidates and regulatory milestones
Financial Metrics
Revenue
N/A
Net Income
-320.6M
EPS (Diluted)
$-2.30
Free Cash Flow
-282.7M
Total Assets
3.3B
Cash
260.8M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-10.7%
ROA
-9.6%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
7.49x
Quick Ratio
7.49x
Debt/Equity
0.00x
Debt/Assets
10.5%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-08T11:54:18.696750 |
Data as of: 2026-03-31 |
Powered by Claude AI